DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Chronic Lymphocytic Leukemia market 2016-2020" report to their offering.
The global CLL therapeutics market is forecast to grow at a CAGR of 19.16% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- F. Hoffman-La Roche
- Teva Pharmaceuticals
- Gilead Sciences
- Johnson & Johnson
- Altor BioScience
- Arno Therapeutics
- Bellicum Pharmaceuticals
- Boston Biomedical
- Emergent BioSolutions
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by ROA
PART 09: Market segmentation by type of molecule
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Appendix
PART 18: About the Author
For more information visit http://www.researchandmarkets.com/research/wkr6hl/global_chronic